Coronavirus illness 2019 (COVID-19) is an infectious illness precipitated by the newly found coronavirus, SARS-CoV-2. Increased severity of COVID-19 has been noticed in sufferers with diabetes mellitus (DM). This research aimed to determine common transcriptional signatures, regulators and pathways between COVID-19 and DM. We have built-in human whole-genome transcriptomic datasets from COVID-19 and DM, adopted by practical evaluation with gene ontology (GO) and pathway analyses.
In peripheral blood mononuclear cells (PBMCs), among the many upregulated differentially expressed genes (DEGs), 32 had been discovered to be generally modulated in COVID-19 and sort 2 diabetes (T2D), whereas 10 DEGs had been generally downregulated. As regards sort 1 diabetes (T1D), 21 DEGs had been generally upregulated, and 29 DEGs had been generally downregulated in COVID-19 and T1D. Moreover, 35 DEGs had been generally upregulated in SARS-CoV-2 contaminated pancreas organoids and T2D islets, whereas 14 had been generally downregulated.
Several GO phrases had been present in common between COVID-19 and DM. Prediction of the putative transcription components concerned within the upregulation of genes in COVID-19 and DM recognized RELA to be implicated in each PBMCs and pancreas. Here, for the primary time, we have now characterised the organic processes and pathways generally dysregulated in COVID-19 and DM, which might be within the subsequent future used for the design of customized remedy of COVID-19 sufferers affected by DM as comorbidity.
Cisplatin’s potential for sort 2 diabetes repositioning by inhibiting CDKN1A, FAS, and SESN1
Cisplatin is a DNA-damaging chemotherapeutic agent used for treating most cancers. Based on cDNA dataset analysis, we investigated how cisplatin modified gene expression and noticed cisplatin-induced dysregulation and system-level variations referring to insulin resistance and sort 2 diabetes mellitus (T2DM). T2DM is a multifactorial illness affecting 462 million individuals on the planet, and drug-induced T2DM is a severe problem.
To perceive this etiology, we designed an integrative, system-level research to determine associations between cisplatin-induced differentially expressed genes (DEGs) and T2DM. From an inventory of differential expressed genes, cisplatin downregulated the cyclin-dependent kinase inhibitor 1 (CDKN1A), tumor necrosis issue (FAS), and sestrin-1 (SESN1) genes chargeable for modifying signaling pathways, together with the p53, JAK-STAT, FOXO, MAPK, mTOR, P13-AKT, Toll-like receptor (TLR), adipocytokine, and insulin signaling pathways. These enriched pathways had been expressively related to the illness.
We noticed important gene signatures, together with SMAD3, IRS, PDK1, PRKAA1, AKT, SOS, RAS, GRB2, MEK1/2, and ERK, interacting with supply genes. This research revealed the worth of system genetics for figuring out the cisplatin-induced genetic variants chargeable for the development of T2DM. Also, by cross-validating gene expression information for T2DM islets, we discovered that downregulating IRS and PRK households is important in insulin and T2DM signaling pathways.
Cisplatin, by inhibiting CDKN1A, FAS, and SESN1, promotes IRS and PRK exercise in the same technique to rosiglitazone (a preferred drug used for T2DM remedy). Our integrative, network-based strategy might help in understanding the drug-induced pathophysiological mechanisms of diabetes.
Relationship between cardiovascular and kidney disease in a sample of patients with diabetes in today’s world
Kidney disease is one of the microvascular complications of diabetes mellitus (DM) with little research and a great relationship with cardiovascular disease (CVD). The objective of this work is to characterize the prevalence of kidney disease in a population of patients with type 2 diabetes who attend outpatient management by cardiology, determine its degree of investigation and its possible effect on the achievement of therapeutic objectives and the use of antidiabetics with cardiorenal protective effect.
Methods: Cross-sectional, observational and multicenter study carried out in 44 centers in Argentina between May and July 2019. Results: 693 patients were included with an established CVD prevalence of 47.5% (329 patients) and 42.3% of microvascular disease . Albuminuria was only assessed in 46.2% of the patients and it was significantly higher in the group with IR. CVD in patients with IR was higher than in those without IR (64.8% vs. 42.2%; p = 0.0001). The presence of albuminuria was accompanied by a higher prevalence of CVD.
The scope of the therapeutic targets was limited and no differences were recognized as a function of RI, with the exception of the LDL target. Low prescription of antidiabetic drugs with proven cardiorenal benefit was observed. Conclusions: The work highlights the importance of the active search for kidney disease in patients with diabetes, which reveals the low scope of therapeutic goals and the prescription of antidiabetic drugs with cardiorenal benefit.
Evaluation of affiliation research and a scientific evaluation and meta-analysis of VDR polymorphisms in sort 2 diabetes mellitus threat
Numerous unique research and four revealed meta-analyses have reported the affiliation between the Vitamin D receptor (VDR) BsmI, FokI, ApaI, and TaqI polymorphisms and sort 2 diabetes mellitus (T2DM) threat. However, the outcomes had been inconsistent.
Therefore, an up to date meta-analysis was carried out to additional discover these points.To additional discover the affiliation between the VDR BsmI, FokI, ApaI, and TaqI polymorphisms and T2DM threat.PubMed, EMBASE, Scopus, and Wanfang databases had been searched. The following search technique had been used: (VDR OR vitamin D receptor) AND (polymorphism OR variant OR mutation) AND (diabetes OR mellitus OR diabetes mellitus).
Pooled crude odds ratios with 95% confidence intervals had been utilized to guage the energy of affiliation in 5 genetic fashions. Statistical heterogeneity, the take a look at of publication bias, and sensitivity analysis had been carried out utilizing the STATA software program (Version 12.0). To consider the credibility of statistically important associations, we utilized the false-positive report chances (FPRP) and Bayesian false discovery chance (BFDP) take a look at.
Overall, the VDR BsmI polymorphism was related to a considerably decreased T2DM threat in Asians; the VDR FokI polymorphism was related to a considerably decreased T2DM threat in Asians, African international locations, and Asian international locations; the VDR ApaI polymorphism was related to a considerably decreased T2DM threat in Caucasians and North American international locations.On the VDR ApaI polymorphism, a considerably elevated T2DM threat was present in a blended inhabitants.
CXCL8 CRISPR Knock Out L3.6pl Cell Line |
|||
T6220 | ABM | 1x10^6 cells / 1.0 ml | Ask for price |
CXCL1 CRISPR Knock Out L3.6pl Cell Line |
|||
T6221 | ABM | 1x10^6 cells / 1.0 ml | Ask for price |
SIRT CRISPR Knock Out Human HepG2 Cell Line - Clone T3-6 |
|||
T6804 | ABM | 1x10^6 cells / 1.0 ml | Ask for price |
PRSS21 CRISPR Knock Out Human OVCAR8 Cell Line - Clone T2 C8 |
|||
T6811 | ABM | 1x10^6 cells / 1.0 ml | Ask for price |
mAdrb2 CRISPR Knock Out B16 Cell Line (T1-10) |
|||
T9775 | ABM | 1x10^6 cells / 1.0 ml | Ask for price |
HeLa/GFP Cell Line |
|||
AKR-213 | Cell Biolabs | 1 vial | 460 EUR |
HeLa/Cas9 Cell Line |
|||
AKR-5111 | Cell Biolabs | 1 vial | 460 EUR |
PTPN6 CRISPR Knock Out Human THP-1 Cell Line - Clone T3-1 |
|||
T6813 | ABM | 1x10^6 cells / 1.0 ml | Ask for price |
MSLN CRISPR Knock Out Human OVCAR3-A1 Cell Line - Clone T2 C4 |
|||
T6820 | ABM | 1x10^6 cells / 1.0 ml | Ask for price |
NUAK2 CRISPR Knock Out 293T Cell Line - Clone T3 #41 |
|||
T6801 | ABM | 1x10^6 cells / 1.0 ml | Ask for price |
NR2F6 CRISPR Knock Out Human Jurkat E6.1 Cell Line - Clone T3-10 |
|||
T6822 | ABM | 1x10^6 cells / 1.0 ml | Ask for price |
Aldh2 CRISPR Knock Out L929 Cell Line - Clone T3-20 |
|||
T9692 | ABM | 1x10^6 cells / 1.0 ml | Ask for price |
hPIM1 CRISPR Knock Out SACC-83 Cell Line-T3-9 |
|||
T9787 | ABM | 1x10^6 cells / 1.0 ml | Ask for price |
Dcx CRISPR Knock Out C6 Cell Line (Rat) - Clone sg4-1 |
|||
T9624 | ABM | 1x10^6 cells / 1.0 ml | 3950 EUR |
GLT1 CRISPR Knock Out Rat AST Cell Line - Clone T2-1 |
|||
T9678 | ABM | 1x10^6 cells / 1.0 ml | Ask for price |
PTPN11 CRISPR Knock Out NIH/3T3 Cell Line - Clone T4-9 |
|||
T6803 | ABM | 1x10^6 cells / 1.0 ml | Ask for price |
METTL3 CRISPR Knock Out Caki-1 Cell Line - Clone T2-16 |
|||
T9623 | ABM | 1x10^6 cells / 1.0 ml | 3950 EUR |
Nacc1 CRISPR Knock Out ID8 Cell Line (Mouse) - Clone T1-23 |
|||
T9627 | ABM | 1x10^6 cells / 1.0 ml | Ask for price |
DJ-1 CRISPR Stable Knockout HeLa Cell Line |
|||
T6181 | ABM | 1x10^6 cells / 1.0 ml | 3950 EUR |
osbpl2 CRISPR Knock Out NIH/3T3 Cell Line - T1 Polyclonal Pool |
|||
T9682 | ABM | 1x10^6 cells / 1.0 ml | Ask for price |
CARMIL1 CRISPR Knock Out Immortalized Human Gingival Fibroblast - hTERT Cell Line - T1-2 |
|||
T6825 | ABM | 1x10^6 cells / 1.0 ml | Ask for price |
LIMD1-/- CRISPR Stable Knockout HeLa Cell Line |
|||
T6357 | ABM | 1x10^6 cells / 1.0 ml | 3950 EUR |
Aifm1 CRISPR Knock Out Mouse L929 Cell Line - Clone T2-15-3 |
|||
T9674 | ABM | 1x10^6 cells / 1.0 ml | Ask for price |
SEC61G CRISPR Knock Out HCC-LM3 Cell Line - Clone T2-17-5 |
|||
T9746 | ABM | 1x10^6 cells / 1.0 ml | Ask for price |
Human RRAD knockout cell line |
|||
ABC-KH13200 | AcceGen | 1 vial | Ask for price |
Description: Human RRAD knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human RRAD knockdown cell line |
|||
ABC-KD13200 | AcceGen | 1 vial | Ask for price |
Description: Human RRAD knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest. |
|||
Cell line gene knock-in and knock-out |
|||
S301 | 101Bio | - | 15000 EUR |
SIRT7 Stable Knockdown HeLa Cell Line |
|||
T6164 | ABM | 1x10^6 cells / 1.0 ml | 3950 EUR |
RanBPM ShRNA Stable Knockout HeLa Cell Line |
|||
T6313 | ABM | 1x10^6 cells / 1.0 ml | 3950 EUR |
Araf CRISPR Knocked out RAW264.7 Stable cell Cell Line (Mouse) T3-3 |
|||
T9529 | ABM | 1x10^6 cells/1.0ml | 3950 EUR |
Araf CRISPR Knocked out RAW264.7 Stable cell Cell Line (Mouse) T1-19 |
|||
T9511 | ABM | 1x10^6 cells / 1.0 ml | 3950 EUR |
MAPRE1 Doxycycline Inducible Knockout HeLa Cell Line |
|||
T6173 | ABM | 1x10^6 cells / 1.0 ml | 3950 EUR |
Stable Mouse Myeloid-derived Suppressor-like LAL Knock Out (HD1B) Cell Line |
|||
T3187 | ABM | 1x10^6 cells / 1.0 ml | 3950 EUR |
MAPRE1/MAPRE3 Doxycycline Inducible Double Knockout HeLa Cell Line |
|||
T6174 | ABM | 1x10^6 cells / 1.0 ml | 3950 EUR |
Hela Cell Line |
|||
CL-0101 | Elabscience Biotech | 1×10⁶ cells/vial | 420 EUR |
Description: Homo sapiens, Human |
|||
HeLa Cell Lysate (Human epithelial Cell Line) |
|||
LF-R0001 | Abfrontier | 200 ul | 103.2 EUR |
Description: HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate |
|||
cDNA - Human Tumor Cell Line: Hela |
|||
C1255811 | Biochain | 40 reactions | 424 EUR |
Hela 229 cell line |
|||
CL-0634 | Elabscience Biotech | 1×10⁶ cells/vial | 500 EUR |
Description: Homo sapiens, human |
|||
Human HRE Reporter Cell Line–HeLa |
|||
ABC-RC0095 | AcceGen | 1 vial | Ask for price |
Description: Human HRE Reporter Cell Line is derived from HeLa cell. Gentaur can provide high quality reporter cell line for monitoring biological activity |
|||
Hela S3 cell line |
|||
CL-0350 | Elabscience Biotech | 1×10⁶ cells/vial | 500 EUR |
Description: Homo sapiens, human |
|||
Human NIS Stable Expressing HeLa Cell Line |
|||
T6491 | ABM | 1x10^6 cells / 1.0 ml | Ask for price |
Human ATF6 Reporter Cell Line–HeLa |
|||
ABC-RC0080 | AcceGen | 1 vial | Ask for price |
Description: Human ATF6 Reporter Cell Line is derived from HeLa cells. It can be used for monitoring biological activity |
|||
Human ACE2 Stable Expressing HeLa Cell Line |
|||
T6044 | ABM | 1x10^6 cells / 1.0 ml | 3950 EUR |
Purified Exosomes: HeLa Human Cell Line |
|||
EXOP-405A-1 | SBI | 50 µg | 409 EUR |
BRCA1 CRISPR Stable Knockout Human Fibroblast Cell Line |
|||
T6245 | ABM | 1x10^6 cells / 1.0 ml | 3950 EUR |
Total RNA - Human Tumor Cell Line: Hela |
|||
R1255811-50 | Biochain | 50 ug | 229 EUR |
H2O2 stimulated HeLa Cell Lysate (Human epithelial cell line) |
|||
LF-R0002 | Abfrontier | Each 100 ul | 145.2 EUR |
Description: HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate - H2O2 stimulated |
|||
Genomic DNA - Human Tumor Cell Line: Hela |
|||
D1255811 | Biochain | 100 ug | 282 EUR |
293AD Cell Line |
|||
AD-100 | Cell Biolabs | 1 vial | 365 EUR |
HeLa/GFP Cell Line |
|||
MBS168642-1Vial | MyBiosource | 1Vial | 650 EUR |
HeLa/GFP Cell Line |
|||
MBS168642-5x1Vial | MyBiosource | 5x1Vial | 2675 EUR |
293AAV Cell Line |
|||
AAV-100 | Cell Biolabs | 1 vial | 405 EUR |
293LTV Cell Line |
|||
LTV-100 | Cell Biolabs | 1 vial | 405 EUR |
293RTV Cell Line |
|||
RV-100 | Cell Biolabs | 1 vial | 405 EUR |
Total Protein - Human Tumor Cell Line: Hela |
|||
P1255811 | Biochain | 1 mg | 216 EUR |
PTPRA CRISPR Knockout Immortalized Human Lung Fibroblast Cell Line |
|||
T6827 | ABM | 1x10^6 cells / 1.0 ml | Ask for price |
Membrane Protein - Human Tumor Cell Line: Hela |
|||
P3255811 | Biochain | 0.1 mg | 311 EUR |
ATF6 Reporter HeLa Cell Line |
|||
MBS668848-1Vial | MyBiosource | 1Vial | 1960 EUR |
ATF6 Reporter HeLa Cell Line |
|||
MBS668848-5x1Vial | MyBiosource | 5x1Vial | 8630 EUR |
HRE Leeporter HeLa Cell Line |
|||
MBS668854-1Vial | MyBiosource | 1Vial | 1960 EUR |
HRE Leeporter HeLa Cell Line |
|||
MBS668854-5x1Vial | MyBiosource | 5x1Vial | 8630 EUR |
p53 Leeporter HeLa Cell Line |
|||
MBS668869-1Vial | MyBiosource | 1Vial | 1960 EUR |
p53 Leeporter HeLa Cell Line |
|||
MBS668869-5x1Vial | MyBiosource | 5x1Vial | 8630 EUR |
Human p53 Luciferase Reporter Cell Line- HeLa |
|||
ABC-RC0037 | AcceGen | 1 vial | Ask for price |
Description: Human p53 Luciferase Reporter Cell Line- HeLa is derived from human cervical cancer, and stably express firefly luciferase reporter gene under the control of the p53 response element. This cell line is an ideal cellular model for monitoring the activation of p53 Receptor Signaling Pathway triggered by stimuli treatment, enforced gene expression and gene knockdown. |
|||
GCaMP6s Stable HeLa Cell Line |
|||
T6483 | ABM | 1x10^6 cells / 1.0 ml | 3950 EUR |
Human NFAT Luciferase Reporter Cell Line- HeLa |
|||
ABC-RC0023 | AcceGen | 1 vial | Ask for price |
Description: Human NFAT Luciferase Reporter Cell Line- HeLa is derived from human cervical cancer, and stably express firefly luciferase reporter gene under the control of NFAT response element. This cell line is an ideal cellular model for monitoring the activation of Calcium Signaling Receptor Signaling Pathway triggered by stimuli treatment, enforced gene expression and gene knockdown. |
|||
293/GFP Cell Line |
|||
AKR-200 | Cell Biolabs | 1 vial | 460 EUR |
Cas9 Expressing HeLa Cell Line |
|||
T3254 | ABM | 1x10^6 cells / 1.0 ml | 795 EUR |
STAT1 Leeporter HeLa Cell Line |
|||
MBS668877-1Vial | MyBiosource | 1Vial | 4615 EUR |
STAT1 Leeporter HeLa Cell Line |
|||
MBS668877-5x1Vial | MyBiosource | 5x1Vial | 20580 EUR |
T47D/GFP Cell Line |
|||
AKR-208 | Cell Biolabs | 1 vial | 686.4 EUR |
Description: T47D/GFP Cell Line stably expresses GFP and otherwise exhibits the same characteristics of the parental cell line. |
|||
A549/GFP Cell Line |
|||
AKR-209 | Cell Biolabs | 1 vial | 460 EUR |
293/Cas9 Cell Line |
|||
AKR-5110 | Cell Biolabs | 1 vial | 460 EUR |
Human Stat1 Luciferase Reporter Cell Line- Hela |
|||
ABC-RC0040 | AcceGen | 1 vial | Ask for price |
Description: Human Stat1 Luciferase Reporter Cell Line- Hela is derived from human cervical cancer,and stably express firefly luciferase reporter gene under the control of the STAT1 response element. This cell line is an ideal cellular model for monitoring the activation of JAK-STAT Receptor Signaling Pathway triggered by stimuli treatment, enforced gene expression and gene knockdown. |
|||
Human Stat3 Luciferase Reporter Cell Line- Hela |
|||
ABC-RC0041 | AcceGen | 1 vial | Ask for price |
Description: Human Stat3 Luciferase Reporter Cell Line- Hela is derived from human cervical cancer, and stably express firefly luciferase reporter gene under the control of the STAT3 response element. This cell line is an ideal cellular model for monitoring the activation of JAK-STAT Receptor Signaling Pathway triggered by stimuli treatment, enforced gene expression and gene knockdown. |
|||
NIH3T3/GFP Cell Line |
|||
AKR-214 | Cell Biolabs | 1 vial | 460 EUR |
NIH3T3/Cas9 Cell Line |
|||
AKR-5104 | Cell Biolabs | 1 vial | 460 EUR |
Human CRISP1 knockout cell line |
|||
ABC-KH3569 | AcceGen | 1 vial | Ask for price |
Description: Human CRISP1 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human CRISP2 knockout cell line |
|||
ABC-KH3570 | AcceGen | 1 vial | Ask for price |
Description: Human CRISP2 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human CRISP3 knockout cell line |
|||
ABC-KH3571 | AcceGen | 1 vial | Ask for price |
Description: Human CRISP3 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human TLR4/IL-8 Reporter Cell Line– HeLa |
|||
ABC-RC0131 | AcceGen | 1 vial | Ask for price |
Description: Human TLR4/IL-8 Reporter Cell Line is derived from HeLa. This reporter cell line is an ideal product to monitor the blogical ativity |
|||
MCF-7/Luc Cell Line |
|||
AKR-234 | Cell Biolabs | 1 vial | 686.4 EUR |
Description: MCF-7/Luc Cell Line stably expresses luciferase and otherwise exhibits the same characteristics of the parental cell line. |
|||
SKOV-3/Luc Cell Line |
|||
AKR-232 | Cell Biolabs | 1 vial | 686.4 EUR |
Description: SKOV-3/Luc Cell Line stably expresses luciferase and otherwise exhibits the same characteristics of the parental cell line. |
|||
PTPN6 Stable Knocked Out THP-1 Cell Line |
|||
T6216 | ABM | 1x10^6 cells / 1.0 ml | 3950 EUR |
OVCAR-5/RFP Cell Line |
|||
AKR-254 | Cell Biolabs | 1 vial | 686.4 EUR |
Description: OVCAR-5/RFP Cell Line stably expresses RFP and otherwise exhibits the same characteristics of the parental cell line. |
|||
Acan CRISPR Knockout RCS Cell Line (Rat) |
|||
T3000 | ABM | 1x10^6 cells / 1.0 ml | Ask for price |
Human CRISPLD1 knockout cell line |
|||
ABC-KH3572 | AcceGen | 1 vial | Ask for price |
Description: Human CRISPLD1 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human CRISPLD2 knockout cell line |
|||
ABC-KH3573 | AcceGen | 1 vial | Ask for price |
Description: Human CRISPLD2 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human CRISP1 knockdown cell line |
|||
ABC-KD3569 | AcceGen | 1 vial | Ask for price |
Description: Human CRISP1 knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest. |
|||
Human CRISP2 knockdown cell line |
|||
ABC-KD3570 | AcceGen | 1 vial | Ask for price |
Description: Human CRISP2 knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest. |
|||
Human CRISP3 knockdown cell line |
|||
ABC-KD3571 | AcceGen | 1 vial | Ask for price |
Description: Human CRISP3 knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest. |
|||
Fat-1 Stable HeLa Cell Line |
|||
T6260 | ABM | 1x10^6 cells / 1.0 ml | 3950 EUR |
Human TCF/LEF Luciferase Reporter Cell Line- HeLa |
|||
ABC-RC0043 | AcceGen | 1 vial | Ask for price |
Description: Human TCF/LEF Luciferase Reporter Cell Line- HeLa is derived from human cervical cancer, and stably express firefly luciferase reporter gene under the control of TCF/LEF response element. This cell line is an ideal cellular model for monitoring the activation of Wnt/b-catenin Signaling Receptor Signaling Pathway triggered by stimuli treatment, enforced gene expression and gene knockdown. |
|||
GFP/HeLa Stable Cell Line |
|||
MBS669606-1Vial | MyBiosource | 1Vial | 2850 EUR |
GFP/HeLa Stable Cell Line |
|||
MBS669606-5x1Vial | MyBiosource | 5x1Vial | 12650 EUR |
NFAT-GFP Stable HeLa Cell Line |
|||
T6484 | ABM | 1x10^6 cells / 1.0 ml | 3950 EUR |
UBG76V-GFP Stable HeLa Cell Line |
|||
T6273 | ABM | 1x10^6 cells / 1.0 ml | 3950 EUR |
TARGATT? Knock-in Mouse Cell Line Generation Kit (Master Cell Line) |
|||
AST-7001 | Applied StemCell | 1 Kit | Ask for price |
Description: 6 month |
|||
RFP Stably Expressing Hela Cell Line |
|||
T3945 | ABM | 1x10^6 cells / 1.0 ml | 1450 EUR |
SIRT7 Stable Scramble HeLa Cell Line |
|||
T6258 | ABM | 1x10^6 cells / 1.0 ml | 3950 EUR |
GFP Stably Expressing Hela Cell Line |
|||
T3903 | ABM | 1x10^6 cells / 1.0 ml | 1450 EUR |
Human CRISPLD1 knockdown cell line |
|||
ABC-KD3572 | AcceGen | 1 vial | Ask for price |
Description: Human CRISPLD1 knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest. |
|||
Human CRISPLD2 knockdown cell line |
|||
ABC-KD3573 | AcceGen | 1 vial | Ask for price |
Description: Human CRISPLD2 knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest. |
|||
ACE2 - HeLa Recombinant Cell Line |
|||
79958 | BPS Bioscience | 2 vials | 4950 EUR |
Description: Recombinant clonal stable HeLa cell line constitutively expressing full length human ACE2, Genbank #NM_021804.3). Surface expression of ACE2 was confirmed by flow cytometry. |
|||
Human RRAS knockout cell line |
|||
ABC-KH13205 | AcceGen | 1 vial | Ask for price |
Description: Human RRAS knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human RRAGA knockout cell line |
|||
ABC-KH13201 | AcceGen | 1 vial | Ask for price |
Description: Human RRAGA knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human RRAGB knockout cell line |
|||
ABC-KH13202 | AcceGen | 1 vial | Ask for price |
Description: Human RRAGB knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human RRAGC knockout cell line |
|||
ABC-KH13203 | AcceGen | 1 vial | Ask for price |
Description: Human RRAGC knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human RRAGD knockout cell line |
|||
ABC-KH13204 | AcceGen | 1 vial | Ask for price |
Description: Human RRAGD knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human RRAS2 knockout cell line |
|||
ABC-KH13206 | AcceGen | 1 vial | Ask for price |
Description: Human RRAS2 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
GFAT1 CRISPR Stable Knockout H1299 Cell Line |
|||
T6199 | ABM | 1x10^6 cells / 1.0 ml | 3950 EUR |
Rrad 3'UTR GFP Stable Cell Line |
|||
TU168183 | ABM | 1.0 ml | Ask for price |
Rrad 3'UTR GFP Stable Cell Line |
|||
TU269725 | ABM | 1.0 ml | Ask for price |
RRAD 3'UTR GFP Stable Cell Line |
|||
TU072380 | ABM | 1.0 ml | 1672.8 EUR |
EDC4 CRISPR Stable Knockout HEK293T Cell Line |
|||
T6241 | ABM | 1x10^6 cells / 1.0 ml | 3950 EUR |
Human INF-a/ISRE Luciferase Reporter Cell Line- HeLa |
|||
ABC-RC0019 | AcceGen | 1 vial | Ask for price |
Description: Human INF-a/ISRE Luciferase Reporter Cell Line- HeLa is derived human cervical cancer, and stably express firefly luciferase reporter gene under the control of IFN-α/ISRE response element. This cell line is an ideal cellular model for monitoring the activation of TYK2 and JAK1 response Pathway triggered by stimuli treatment, enforced gene expression and gene knockdown. |
|||
TLR4/IL-8 Leeporter HeLa Cell Line |
|||
MBS668887-1Vial | MyBiosource | 1Vial | 6535 EUR |
TLR4/IL-8 Leeporter HeLa Cell Line |
|||
MBS668887-5x1Vial | MyBiosource | 5x1Vial | 29220 EUR |
PDPN CRISPR Stable Knockout COS-7 Cell Line |
|||
T6039 | ABM | 1x10^6 cells / 1.0 ml | 3950 EUR |
PD-L1 CRISPR Stable Knockout CT26 Cell Line |
|||
T6237 | ABM | 1x10^6 cells / 1.0 ml | 3950 EUR |
PD-L1 CRISPR Stable Knockout MC38 Cell Line |
|||
T6149 | ABM | 1x10^6 cells / 1.0 ml | 3950 EUR |
Human RRAS knockdown cell line |
|||
ABC-KD13205 | AcceGen | 1 vial | Ask for price |
Description: Human RRAS knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest. |
|||
TARGATT? Knock-in iPSC Generation (Master Cell Line) |
|||
AST-1100 | Applied StemCell | 1 vial of 1X10^6 cells | Ask for price |
Description: 6 month |
|||
Human RRAGA knockdown cell line |
|||
ABC-KD13201 | AcceGen | 1 vial | Ask for price |
Description: Human RRAGA knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest. |
|||
Human RRAGB knockdown cell line |
|||
ABC-KD13202 | AcceGen | 1 vial | Ask for price |
Description: Human RRAGB knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest. |
|||
Human RRAGC knockdown cell line |
|||
ABC-KD13203 | AcceGen | 1 vial | Ask for price |
Description: Human RRAGC knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest. |
|||
Human RRAGD knockdown cell line |
|||
ABC-KD13204 | AcceGen | 1 vial | Ask for price |
Description: Human RRAGD knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest. |
|||
Human RRAS2 knockdown cell line |
|||
ABC-KD13206 | AcceGen | 1 vial | Ask for price |
Description: Human RRAS2 knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest. |
|||
Hela / Cas9 (Bad) Stable Cell Line |
|||
SC045-Cas9-Bsd | GenTarget | 2 x 106 cell/ml x 1ml | 1269.6 EUR |
Description: Cas9 expression stable cell line with Blasticidin resistance in Hela human cervical cancer cells. |
|||
Platinum-E Retroviral Packaging Cell Line, Ecotropic |
|||
RV-101 | Cell Biolabs | 1 vial | 770 EUR |
RRAD 3'UTR Luciferase Stable Cell Line |
|||
TU022380 | ABM | 1.0 ml | 1672.8 EUR |
Rrad 3'UTR Luciferase Stable Cell Line |
|||
TU118183 | ABM | 1.0 ml | Ask for price |
Rrad 3'UTR Luciferase Stable Cell Line |
|||
TU219725 | ABM | 1.0 ml | Ask for price |
Platinum-GP Retroviral Packaging Cell Line, Pantropic |
|||
RV-103 | Cell Biolabs | 1 vial | 770 EUR |
Platinum-A Retroviral Packaging Cell Line, Amphotropic |
|||
RV-102 | Cell Biolabs | 1 vial | 770 EUR |
SLC35A1 CRISPR Stable Knockout CHO-S Cell Line |
|||
T6040 | ABM | 1x10^6 cells / 1.0 ml | 3950 EUR |
CXCL1 & CXCL8 CRISPR Double Knockout L3.6pl Cell Line |
|||
T6047 | ABM | 1x10^6 cells / 1.0 ml | Ask for price |
Whale NIS Stable Expressing HeLa Cell Line |
|||
T6492 | ABM | 1x10^6 cells / 1.0 ml | Ask for price |
Zebra NIS Stable Expressing HeLa Cell Line |
|||
T6493 | ABM | 1x10^6 cells / 1.0 ml | Ask for price |
Total Protein - Murine Embryonic Stem Cell Line D3 |
|||
CBA-305 | Cell Biolabs | 500 ?g | 414 EUR |
Description:
|
|||
Inducible GFP Hela stable cell line |
|||
SC036 | GenTarget | 2 x 106 cell/ml x 1ml | 1800 EUR |
Description: InducibleGFP expression stable cell line in Hela cells, with Neomycin and puromycin resitance |
|||
Inducible RFP Hela stable cell line |
|||
SC037 | GenTarget | 2 x 106 cell/ml x 1ml | 1800 EUR |
Description: Inducible RFP expression stable cell line in Hela with Blasticidin and Puromycin resistance |
|||
RRAD sgRNA CRISPR Lentivector set (Human) |
|||
K2069901 | ABM | 3 x 1.0 ug | 406.8 EUR |
PLN Knock-out Human Induced Pluripotent Stem Cells (Episomal, HFF) |
|||
iPS41 | ALSTEM | 1 Vial | 2268 EUR |
AXL CRISPR Stable Knockout HT1080 (1-IV) Cell Line |
|||
T6232 | ABM | 1x10^6 cells / 1.0 ml | 3950 EUR |
AXL CRISPR Stable Knockout HT1080 (3-II) Cell Line |
|||
T6233 | ABM | 1x10^6 cells / 1.0 ml | 3950 EUR |
LRP1 Knock-out Human Induced Pluripotent Stem Cells (Episomal, HFF) |
|||
iPS31 | ALSTEM | 1 Vial | 2268 EUR |
AFF2 Knock-out Human Induced Pluripotent Stem Cells (Episomal, HFF) |
|||
iPS61 | ALSTEM | 1 Vial | 2268 EUR |
Human HELB knockout cell line |
|||
ABC-KH6684 | AcceGen | 1 vial | Ask for price |
Description: Human HELB knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human HELQ knockout cell line |
|||
ABC-KH6686 | AcceGen | 1 vial | Ask for price |
Description: Human HELQ knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
However, once we additional carried out a sensitivity analysis, FPRP, and BFDP take a look at, less-credible optimistic outcomes had been recognized (all FPRP > 0.2 and BFDP > 0.8) in any important affiliation.In abstract, this research strongly signifies that every one important associations had been much less credible optimistic outcomes, fairly than from true associations.